Loading...

SCYNEXIS

Nasdaq:SCYX
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SCYX
Nasdaq
$36M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. The last earnings update was 72 days ago. More info.


Add to Portfolio Compare Print
  • SCYNEXIS has significant price volatility in the past 3 months.
SCYX Share Price and Events
7 Day Returns
-5.4%
NasdaqGM:SCYX
-0%
US Pharmaceuticals
0.7%
US Market
1 Year Returns
-60.5%
NasdaqGM:SCYX
-0.8%
US Pharmaceuticals
-8.1%
US Market
SCYX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
SCYNEXIS (SCYX) -5.4% 78.4% -28.8% -60.5% -84.8% -
US Pharmaceuticals -0% 4.3% -2.1% -0.8% 8.3% 22.7%
US Market 0.7% 10.2% -1% -8.1% 38.8% 38.9%
1 Year Return vs Industry and Market
  • SCYX underperformed the Pharmaceuticals industry which returned -0.8% over the past year.
  • SCYX underperformed the Market in United States of America which returned -8.1% over the past year.
Price Volatility
SCYX
Industry
5yr Volatility vs Market

SCYX Value

 Is SCYNEXIS undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for SCYNEXIS. This is due to cash flow or dividend data being unavailable. The share price is $0.726.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for SCYNEXIS's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are SCYNEXIS's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:SCYX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-0.56
NasdaqGM:SCYX Share Price ** NasdaqGM (2019-01-23) in USD $0.73
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 27 Publicly-Listed Pharmaceuticals Companies 19.24x
United States of America Market PE Ratio Median Figure of 3,026 Publicly-Listed Companies 16.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of SCYNEXIS.

NasdaqGM:SCYX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:SCYX Share Price ÷ EPS (both in USD)

= 0.73 ÷ -0.56

-1.29x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SCYNEXIS is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • SCYNEXIS is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does SCYNEXIS's expected growth come at a high price?
Raw Data
NasdaqGM:SCYX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.29x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
22.4%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 22 Publicly-Listed Pharmaceuticals Companies 1.11x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.26x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for SCYNEXIS, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on SCYNEXIS's assets?
Raw Data
NasdaqGM:SCYX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $0.59
NasdaqGM:SCYX Share Price * NasdaqGM (2019-01-23) in USD $0.73
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 171 Publicly-Listed Pharmaceuticals Companies 2.54x
United States of America Market PB Ratio Median Figure of 5,102 Publicly-Listed Companies 1.75x
NasdaqGM:SCYX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:SCYX Share Price ÷ Book Value per Share (both in USD)

= 0.73 ÷ 0.59

1.23x

* Primary Listing of SCYNEXIS.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SCYNEXIS is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess SCYNEXIS's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. SCYNEXIS has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SCYX Future Performance

 How is SCYNEXIS expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is SCYNEXIS expected to grow at an attractive rate?
  • SCYNEXIS's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • SCYNEXIS's earnings growth is expected to exceed the United States of America market average.
  • SCYNEXIS's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:SCYX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:SCYX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 22.4%
NasdaqGM:SCYX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 75.8%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 20.1%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.6%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:SCYX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:SCYX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 135 31 6
2022-12-31 67 -19 6
2021-12-31 22 -55 6
2020-12-31 5 -37 7
2019-12-31 0 -40 7
2018-12-31 0 -22 6
NasdaqGM:SCYX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 0 -27 -22
2018-06-30 0 -27 -31
2018-03-31 0 -26 -24
2017-12-31 0 -25 -25
2017-09-30 0 -24 -21
2017-06-30 0 -26 -24
2017-03-31 0 -27 -28
2016-12-31 0 -29 -30
2016-09-30 0 -31 -35
2016-06-30 0 -30 -31
2016-03-31 0 -29 -30
2015-12-31 0 -25 -28

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • SCYNEXIS's earnings are expected to grow significantly at over 20% yearly.
  • SCYNEXIS's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:SCYX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from SCYNEXIS Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:SCYX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.73 1.82 0.09 4.00
2022-12-31 -0.20 -0.15 -0.24 3.00
2021-12-31 -0.48 -0.36 -0.63 3.00
2020-12-31 -0.64 -0.34 -0.93 5.00
2019-12-31 -0.69 -0.56 -0.87 6.00
2018-12-31 -0.51 -0.49 -0.55 3.00
NasdaqGM:SCYX Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -0.56
2018-06-30 -0.90
2018-03-31 -0.84
2017-12-31 -0.94
2017-09-30 -0.82
2017-06-30 -0.96
2017-03-31 -1.26
2016-12-31 -1.58
2016-09-30 -2.12
2016-06-30 -2.22
2016-03-31 -2.19
2015-12-31 -2.33

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if SCYNEXIS will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess SCYNEXIS's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
SCYNEXIS has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SCYX Past Performance

  How has SCYNEXIS performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare SCYNEXIS's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • SCYNEXIS does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare SCYNEXIS's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare SCYNEXIS's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
SCYNEXIS's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from SCYNEXIS Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:SCYX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 0.26 -22.00 8.35 20.26
2018-06-30 0.26 -30.75 7.93 20.78
2018-03-31 0.26 -24.19 8.16 19.63
2017-12-31 0.26 -25.06 8.25 18.33
2017-09-30 0.26 -20.92 8.14 16.71
2017-06-30 0.26 -23.75 8.01 17.14
2017-03-31 0.26 -27.67 7.33 19.35
2016-12-31 0.26 -29.99 7.80 20.08
2016-09-30 0.26 -34.93 8.62 22.21
2016-06-30 0.26 -31.23 10.89 20.77
2016-03-31 0.26 -29.59 12.49 17.40
2015-12-31 0.26 -28.34 12.17 16.44
2015-09-30 1.26 -23.33 11.66 13.19
2015-06-30 1.26 -19.13 9.64 12.21
2015-03-31 1.26 -11.23 8.62 10.75
2014-12-31 1.26 -7.24 7.62 8.29
2014-09-30 3.87 -41.94 6.81 6.78
2014-06-30 7.97 -42.57 5.83 5.35
2014-03-31 12.13 -46.68 4.50 4.53
2013-12-31 16.86 -46.81 4.38 4.36
2012-12-31 16.84 -11.48 4.74 8.93

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if SCYNEXIS has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if SCYNEXIS has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if SCYNEXIS improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess SCYNEXIS's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
SCYNEXIS has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SCYX Health

 How is SCYNEXIS's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up SCYNEXIS's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • SCYNEXIS is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • SCYNEXIS's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of SCYNEXIS's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from SCYNEXIS Company Filings, last reported 3 months ago.

NasdaqGM:SCYX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 27.88 14.97 49.49
2018-06-30 26.55 14.86 55.19
2018-03-31 36.84 14.76 63.70
2017-12-31 21.41 14.65 43.89
2017-09-30 27.26 14.55 47.71
2017-06-30 31.66 14.45 49.34
2017-03-31 33.53 14.35 54.90
2016-12-31 34.82 14.25 58.59
2016-09-30 33.18 14.17 52.35
2016-06-30 43.88 0.00 50.34
2016-03-31 35.04 0.00 38.02
2015-12-31 41.95 0.00 46.99
2015-09-30 49.97 0.00 53.77
2015-06-30 56.77 0.00 57.06
2015-03-31 27.44 0.00 27.62
2014-12-31 33.43 0.00 32.24
2014-09-30 36.14 0.00 34.04
2014-06-30 39.42 0.00 38.43
2014-03-31 -20.43 15.00 0.65
2013-12-31 -20.92 15.00 1.40
2012-12-31 -19.17 26.44 2.39
  • SCYNEXIS's level of debt (53.7%) compared to net worth is high (greater than 40%).
  • SCYNEXIS had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • SCYNEXIS has sufficient cash runway for 2.9 years based on current free cash flow.
  • SCYNEXIS has sufficient cash runway for 2.8 years if free cash flow continues to grow at historical rates of 5.5% each year.
X
Financial health checks
We assess SCYNEXIS's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. SCYNEXIS has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SCYX Dividends

 What is SCYNEXIS's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from SCYNEXIS dividends.
If you bought $2,000 of SCYNEXIS shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate SCYNEXIS's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate SCYNEXIS's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:SCYX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1986 Stocks 2.6%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.9%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:SCYX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as SCYNEXIS has not reported any payouts.
  • Unable to verify if SCYNEXIS's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of SCYNEXIS's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as SCYNEXIS has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess SCYNEXIS's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can SCYNEXIS afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. SCYNEXIS has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SCYX Management

 What is the CEO of SCYNEXIS's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Marco Taglietti
COMPENSATION $1,220,648
AGE 58
TENURE AS CEO 3.8 years
CEO Bio

Dr. Marco Taglietti, M.D. has been the Chief Executive Officer of SCYNEXIS, Inc. since April 1, 2015 and has been President since September 24, 2015. Dr. Taglietti served as Senior Vice President, Head of Global Research and Development, at Stiefel Laboratories, Inc for three years. He served as the Chief Medical Officer and Executive Vice President of Drug Development & Research at Forest Laboratories Inc. since December 2013. He served as the President of the Forest Research Institute (FRI) of Forest Laboratories Inc. from December 2010 to December 2013. He served as Senior Vice President of Research & Development at Forest Laboratories Inc. from December 2010 to December 2013. He served as an Executive Vice President of Research and Development and Chief Medical Officer of Forest Laboratories. Dr. Taglietti joined Forest in August 2007 as an Executive Vice President of Development and Chief Medical Officer of wholly-owned subsidiary Forest Research Institute, Inc. He served as Vice President of Research & Development of Forest Laboratories Inc. since December 2008. He joined Stiefel after 12 years at Schering-Plough Corporation where he last held the position of Vice President of Worldwide Clinical Research at Anti-Infectives, Oncology, CNS, Endocrinology and Dermatology. Dr. Taglietti began his career at Marion Merrell Dow Research Institute. He also served as President of the Forest Research Institute. He has been a Director of Delcath Systems, Inc. since December 11, 2014 and SCYNEXIS, Inc. since November 2014. He has been a Trustee of BioNJ Inc. since February 25, 2016. Dr. Taglietti serves as Director of TransCelerate BioPharma Inc. He served as an Independent Director of NephroGenex, Inc. since October 1, 2014 until March 6, 2017. He received his medical degree and board certifications from the University of Pavia in Italy.

CEO Compensation
  • Marco's compensation has increased whilst company is loss making.
  • Marco's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the SCYNEXIS management team in years:

3.4
Average Tenure
48
Average Age
  • The tenure for the SCYNEXIS management team is about average.
Management Team

Marco Taglietti

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
58
TENURE
3.8 yrs

Eric Francois

TITLE
Chief Financial Officer
COMPENSATION
$646K
AGE
43
TENURE
3.2 yrs

David Angulo

TITLE
Chief Medical Officer
COMPENSATION
$768K
AGE
53
TENURE
3.6 yrs

Scott Sukenick

TITLE
General Counsel & Corporate Secretary
AGE
40
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the SCYNEXIS board of directors in years:

3.8
Average Tenure
58.5
Average Age
  • The tenure for the SCYNEXIS board of directors is about average.
Board of Directors

Guy MacDonald

TITLE
Chairman of the Board
COMPENSATION
$75K
AGE
59
TENURE
3.6 yrs

Marco Taglietti

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
58
TENURE
4.2 yrs

Ann Hanham

TITLE
Independent Director
COMPENSATION
$74K
AGE
65
TENURE
10.1 yrs

Pat Machado

TITLE
Independent Director
COMPENSATION
$74K
AGE
54
TENURE
3.3 yrs

Dave Hastings

TITLE
Independent Director
COMPENSATION
$73K
AGE
57
TENURE
3.3 yrs

Steve Gilman

TITLE
Independent Director
COMPENSATION
$68K
AGE
65
TENURE
3.9 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by SCYNEXIS insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
14. Jan 19 Buy Marco Taglietti Individual 10. Jan 19 10. Jan 19 25,000 $0.69 $17,250
02. Jan 19 Buy Marco Taglietti Individual 31. Dec 18 31. Dec 18 25,000 $0.46 $11,500
02. Jan 19 Buy David Angulo Individual 31. Dec 18 31. Dec 18 12,000 $0.50 $5,951
10. Sep 18 Buy David Angulo Individual 06. Sep 18 06. Sep 18 7,000 $1.27 $8,890
27. Aug 18 Buy Marco Taglietti Individual 23. Aug 18 23. Aug 18 25,000 $1.29 $32,250
02. Apr 18 Buy David Angulo Individual 29. Mar 18 29. Mar 18 6,000 $1.36 $8,160
12. Mar 18 Buy Marco Taglietti Individual 08. Mar 18 08. Mar 18 100,000 $1.69 $169,000
12. Mar 18 Buy Eric Francois Individual 08. Mar 18 08. Mar 18 5,917 $1.69 $10,000
12. Mar 18 Buy David Angulo Individual 08. Mar 18 08. Mar 18 14,790 $1.69 $24,995
12. Mar 18 Buy David Angulo Individual 08. Mar 18 08. Mar 18 7,000 $1.39 $9,730
12. Mar 18 Buy David Hastings Individual 08. Mar 18 08. Mar 18 11,834 $1.69 $19,999
12. Mar 18 Buy Scott Sukenick Individual 08. Mar 18 08. Mar 18 2,959 $1.69 $5,001
X
Management checks
We assess SCYNEXIS's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. SCYNEXIS has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SCYX News

Simply Wall St News

Could SCYNEXIS, Inc.'s (NASDAQ:SCYX) Investor Composition Influence The Stock Price?

We also tend to see lower insider ownership in companies that were previously publicly owned. … SCYNEXIS is a smaller company with a market capitalization of US$29m, so it may still be flying under the radar of many institutional investors. … We can zoom in on the different ownership groups, to learn more about SCYX

Simply Wall St -

How Much Are SCYNEXIS, Inc. (NASDAQ:SCYX) Insiders Spending On Buying Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in SCYNEXIS, Inc. … It's very possible they regret the purchase, but it's more likely they are bullish about the company. … In the last twelve months there was more buying than selling by SCYNEXIS insiders

Simply Wall St -

What Investors Should Know About SCYNEXIS Inc's (NASDAQ:SCYX) Financial Strength

SCYNEXIS Inc (NASDAQ:SCYX) is a small-cap stock with a market capitalization of US$42m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … So, understanding the company's financial health becomes

Simply Wall St -

Is SCYNEXIS Inc (NASDAQ:SCYX) A Financially Sound Company?

Investors are always looking for growth in small-cap stocks like SCYNEXIS Inc (NASDAQ:SCYX), with a market cap of US$75.42m. … However, an important fact which most ignore is: how financially healthy is the business? … Evaluating financial health as part of your investment thesis is

Simply Wall St -

SCYNEXIS Inc's (NASDAQ:SCYX) Path To Profitability

SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. … The US$80.10m market-cap posted a loss in its most recent financial year of -US$25.06m and a latest trailing-twelve-month loss of -US$24.19m shrinking the gap between loss and breakeven. … View out our latest analysis for SCYNEXIS

Simply Wall St -

Did SCYNEXIS Inc's (NASDAQ:SCYX) Earnings Growth Outperform The Industry?

When SCYNEXIS Inc (NASDAQ:SCYX) announced its most recent earnings (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … View our latest analysis for SCYNEXIS Were SCYX's earnings stronger than its past performances and the industry? … I use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data.

Simply Wall St -

SCYX Company Info

Map
Description

SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.

Details
Name: SCYNEXIS, Inc.
SCYX
Exchange: NasdaqGM
Founded: 1999
$36,458,471
47,971,673
Website: http://www.scynexis.com
Address: SCYNEXIS, Inc.
101 Hudson Street,
Suite 3610,
Jersey City,
New Jersey, 07302,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM SCYX Common Stock Nasdaq Global Market US USD 02. May 2014
DB 135 Common Stock Deutsche Boerse AG DE EUR 02. May 2014
LSE 0L49 Common Stock London Stock Exchange GB USD 02. May 2014
Number of employees
Current staff
Staff numbers
19
SCYNEXIS employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/01/24 00:31
End of day share price update: 2019/01/23 00:00
Last estimates confirmation: 2019/01/04
Last earnings filing: 2018/11/13
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.